Press release
Hereditary Transthyretin Amyloidosis Market Report 2025-2034: Industry Overview, Trends, And Forecast Analysis
Hereditary Transthyretin Amyloidosis
What Is the Current Hereditary Transthyretin Amyloidosis Market Size and Its Estimated Growth Rate?
The market for hereditary transthyretin amyloidosis has experienced a robust growth in the recent past. It is forecasted to expand from $1.36 billion in 2024 to $1.50 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 9.7%. The growth observed during the historic period can be attributed to factors such as the increasing prevalence of the disease, escalating research and development initiatives, a rise in the number of cardiac amyloidosis instances, heightened disease awareness, and an expanded healthcare infrastructure.
In the coming years, the hereditary transthyretin amyloidosis market is projected to experience significant growth, reaching $2.14 billion in 2029 with a compound annual growth rate (CAGR) of 9.4%. This surge during the predicted period can be credited to several factors such as an increasing elderly population, higher disposable income levels, a rise in cases of hereditary transthyretin amyloidosis, advancements in new drug development, and an increase in genetic testing. The forecast period also indicates major trends like cutting-edge therapeutic products, improvement in diagnostic methods, progress in medication development, the need for efficacious therapies, and medical technology advancements.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22003
How Are Emerging Segments Shaping the Hereditary Transthyretin Amyloidosis Market Landscape?
The hereditary transthyretin amyloidosis market covered in this report is segmented -
1) By Type: Oral, Subcutaneous Injection, Other Types
2) By Drug Class: RNAi Agents (Patisiran), Small Interfering RNAs (siRNAs) (Vutrisiran)
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies
4) By Application: Hospital, Clinic, Other Applications
Subsegments:
1) By Oral: Tafamidis, Diflunisal, Experimental Oral Therapies
2) By Subcutaneous Injection: Patisiran, Inotersen, Vutrisiran
3) By Other Types: Intravenous Therapies, Gene Silencing Therapies, CRISPR-Based Therapies
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22003&type=smp
Which Growth Factors Are Influencing Hereditary Transthyretin Amyloidosis Market Expansion?
The hereditary transthyretin amyloidosis market is set to expand due to the anticipated increase in the number of older adults. The term elderly population refers to those over the age of 65, who typically need specialised medical care and assistance as a result of ageing. This segment of the population is on the rise, thanks to improved healthcare and living conditions that have extended life expectancy. Older adults are significantly affected by hereditary transthyretin amyloidosis (hATTR), which results in progressive neuropathy and cardiomyopathy, adding to the health complications of the elderly. The Population Reference Bureau, a non-profit organization in the US, forecasted in January 2024 that the population of Americans aged 65 and over is likely to surge from 58 million in 2022 to 82 million by 2050, indicating a 47% growth. Thus, the increasing elderly population is contributing to the expanding demand in the hereditary transthyretin amyloidosis market.
Who Are the Dominant Players Across Different Hereditary Transthyretin Amyloidosis Market Segments?
Major companies operating in the hereditary transthyretin amyloidosis market are Pfizer Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Novo Nordisk, Regeneron Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., BridgeBio Pharma Inc., Akcea Therapeutics, Prothena Corporation plc, Intellia Therapeutics Inc., YoITech Therapeutics, Corino Therapeutics Inc., Attralus Inc., BSIM Therapeutics SA, Eidos Therapeutics, Autotac Bio Inc.
What Are the Latest Developing Trends in the Hereditary Transthyretin Amyloidosis Market?
Leading businesses in the hereditary transthyretin amyloidosis marketplace are creating novel therapeutic solutions, such as RNAi therapeutics, to identify and decrease transthyretin (TTR) protein levels. RNAi therapeutics belong to a drug category that leverages RNA interference tech to suppress specific genes and subsequently decrease the generation of proteins causing diseases. For example, in October 2024, Alnylam Pharmaceuticals, Inc., a biopharmaceutical firm based in the US, put forward a supplemental new drug application (sNDA) to the US FDA for Vutrisiran (AMVUTTRA) to be utilized as a therapy for transthyretin amyloidosis with cardiomyopathy. This submission emphasizes their groundbreaking RNAi therapeutic method, aimed at identifying and reducing transthyretin (TTR) protein, a major contributor to the progression of the disease. As opposed to traditional intravenous treatments, Vutrisiran's subcutaneous administration provides a more accessible and patient-centric dosage scheme, highlighting it as a potential game-changing option for patients with this severe ailment.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/hereditary-transthyretin-amyloidosis-global-market-report
Which Geographic Regions Are Expected to Dominate the Hereditary Transthyretin Amyloidosis Market in the Coming Years?
North America was the largest region in the hereditary transthyretin amyloidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary transthyretin amyloidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Hereditary Transthyretin Amyloidosis Market?
2. What is the CAGR expected in the Hereditary Transthyretin Amyloidosis Market?
3. What Are the Key Innovations Transforming the Hereditary Transthyretin Amyloidosis Industry?
4. Which Region Is Leading the Hereditary Transthyretin Amyloidosis Market?
Why This Report Matters:
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.
Efficient Research: Quickly identify market growth, leading players, and major segments.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hereditary Transthyretin Amyloidosis Market Report 2025-2034: Industry Overview, Trends, And Forecast Analysis here
News-ID: 3987436 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Hereditary
Unraveling Hereditary Cancer With The Rising Demand For Hereditary Cancer Testin …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Hereditary Cancer Testing Industry Market Size Be by 2025?
The market encompassing hereditary cancer testing has exhibited robust expansion throughout the recent past, projecting an increase from its value of $4.32 billion in 2024 to reach $4.75 billion for the subsequent year, reflecting a consistent annual…
Leber Hereditary Optic Neuropathy Treatment Market
Introduction
Leber Hereditary Optic Neuropathy (LHON) is a genetic condition that leads to severe vision loss, primarily affecting young adults. This disorder is caused by mutations in mitochondrial DNA, which impairs the function of retinal ganglion cells. As awareness of LHON has grown, so too has the focus on its treatment options. The LHON treatment market is evolving rapidly, driven by advancements in genetic therapies, pharmaceuticals, and supportive care strategies. This…
Hereditary Hemochromatosis Market - Redefining Care, Inspiring Hope: Hereditary …
Newark, New Castle, USA: The "Hereditary Hemochromatosis Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Hereditary Hemochromatosis Market: https://www.growthplusreports.com/report/hereditary-hemochromatosis-market/8793
This latest report researches the industry structure, sales, revenue,…
Hereditary Angioedema Market Research Report 2032
DelveInsight's "Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the Hereditary Angioedema, historical and forecasted epidemiology as well as the Hereditary Angioedema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Hereditary Angioedema (HAE) is a rare genetic disorder caused by the deficiency in functional C1 inhibitor (C1INH) that results in recurrent attacks of localized subcutaneous or…
Hereditary Angioedema - Drug Pipeline Landscape, 2022
Global Hereditary Angioedema Market report from Global Insight Services is the single authoritative source of intelligence on hereditary angioedema market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters' and PESTLE analysis. Report includes in-depth segmentation and market size data by categories, product types,…
Hereditary Angioedema - Drug Pipeline Landscape, 2022
Hereditary Angioedema is an infrequent inherited disease that causes substantial swelling in various body tissues, such as the abdomen or face caused by a low level or improper function of a protein called the C1 inhibitor. There are three types of hereditary angioedema namely type I, II, and III.
Hereditary Angioedema is mainly caused by a low level or improper function of a protein called the C1 inhibitor.
Read more about Hereditary…
